About this trial
This pilot study will establish the feasibility of a larger trial to investigate whether reboxetine, a medication used to treat depression, can reduce the severity of obstructive sleep apnea (OSA) including increased blood oxygenation in post-surgical OSA patients where positive airway pressure (CPAP) therapy is either frequently poorly tolerated or not an option immediately post surgery. In this randomized, placebo-controlled, double-blind study, participants will use at-home sleep monitoring equipment before and after surgery plus measures of oxygenation. They will be prescribed either reboxetine or a placebo for seven days after surgery and complete questionnaires at the beginning and end of the study.
Eligibility criteria
Qualifiers
Age >18 years
Undergoing elective upper airway surgery
History of obstructive sleep apnoea (OSA)
Disqualifiers
Clinically significant cardiac disease (e.g., arrhythmia, coronary artery disease, or cardiac failure)
History of clinically significant urinary retention, bladder outlet obstruction, or benign prostatic hyperplasia
Poorly controlled hypertension
Epilepsy
Trial design
Treatments tested in this trial
- Reboxetine 4 MG Oral Tablet
- Placebo
Treatment groups
Sponsors and collaborators
Flinders University
Lead sponsor
Flinders Medical Centre
Collaborator